Table 5. Comparisons of the available meta-analyses evaluating the relationship between testosterone therapy and prostate safety.

Variable	Calof et al (2005) [49]		Fernández-Balsells et al (2010) [51]		Cui and Zhang (2013) [64]		Cui et al (2014) [65]		Guo et al (2016) [67]		Kang et al (2015) [66]		Boyle et al (2016) [62]
No. of trials included	19		51		16		22		16		15		27
No. of patients analyzed	1,084		2,679		1,030		2,351		1,921		1,124		2,213
Inclusion criteria	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
Primary end point prostate safety		×		×	×		×			×		×	×
Data presented according to trial duration		×		×	×		×			×		×		×
Time restriction (>12 wk)	×			×		×		×		×		×		×
Time restriction (>24 wk)		×		×		×		×	×			×		×
Age restriction (≥45 yr)	×			×		×		×		×		×		×
Prostate adverse event analysis
PSA change		×		×	×		×		×			×	×
Prostate volume		×		×	×			×	×			×		×
IPSS	×			×	×			×	×			×		×
Abnormal PSA	×			×		×	×			×	×			×
Prostate biopsy	×		×			×	×			×		×		×
Prostate cancer	×		×			×	×			×		×	×

X indicates if Yes or No. PSA: prostatic specific antigen, IPSS: international prostatic symptoms score.